Maturation of antigen-presenting cells using activated T cells

• US 20030082806A1
• Filed: 04/29/2002
• Published: 05/01/2003
• Est. Priority Date: 04/27/2001
• Status: Abandoned Application

• Current Assignee: Life Technologies Corporation (Thermo Fisher Scientific Incorporated)
• Original Assignee: Xcyte Therapies, Inc. (Cyclacel Pharmaceuticals Incorporated)
• Inventors: Monji, Tatsue, Bonyhadi, Mark, Kalamasz, Dale, Berenson, Ronald Jay, Craig, Stewart
• Application Number:
  US10/136,024
• Publication Number:
  US 20030082806A1
• Time in Patent Office: Days
• US Class Current: 435/372
• CPC Class Codes: A61K 2039/5154 Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
• CPC Class Codes: A61K 2039/5158 Antigen-pulsed cells, e.g. T-cells
• CPC Class Codes: A61K 39/4615 Dendritic cells
• CPC Class Codes: A61K 39/4621 immunosuppressive or immunotolerising
• CPC Class Codes: A61K 39/4622 Antigen presenting cells
• CPC Class Codes: A61K 39/46434 Antigens related to induction of tolerance to non-self
• CPC Class Codes: C12N 2501/22 Colony stimulating factors (G-CSF, GM-CSF)
• CPC Class Codes: C12N 2501/23 Interleukins [IL]
• CPC Class Codes: C12N 2501/51 B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
• CPC Class Codes: C12N 2501/515 CD3, T-cell receptor complex
• CPC Class Codes: C12N 5/0639 Dendritic cells, e.g. Langherhans cells in the epidermis
• CPC Class Codes: C12N 5/16 Animal cells

Abstract

The present invention relates to methods for maturing antigen-presenting cells, and more particularly, to methods for maturing dendritic cells. Methods for generating mature and/or maturing antigen-presenting cells in vitro and in vivo are disclosed. The present invention also relates to compositions of cells, including mature antigen-presenting cells and/or activated T cells and their use in generating immune responses in vivo, and inhibiting the development of or preventing infectious diseases and cancers.

Claims

1. A method for maturing dendritic cells, comprising:

(a) providing a population of cells wherein at least a portion thereof comprises immature dendritic cells; and

(b) exposing the population of cells to activated T cells or supernatant therefrom, thereby inducing maturation.

2. The method of claim 1 wherein the immature dendritic cells are generated from a source of precursor cells selected from the group consisting of leukapheresis product, peripheral blood, lymph node, skin, GALT, tonsil, thymus, tissue biopsy, tumor, spleen, skin, bone marrow, cord blood, CD34⁺ cells, monocytes, and adherent cells.

3. The method of claim 2 wherein the immature dendritic cells are generated by exposing the precursor cells to activated T cells or supernatant therefrom.

4. The method of claim 1 wherein the immature dendritic cells comprise dendritic/tumor cell fusions.

5. The method of claim 4 wherein the tumor cells used to generate the dendritic/tumor cell fusions are from a cancer.

6. The method of claim 5 wherein the cancer is selected from the group consisting of

7. The method of claim 1 wherein the immature dendritic cells are generated from a source of precursor cells selected from the group consisting of leukapheresis product, peripheral blood, lymph node, skin, GALT, tonsil, thymus, tissue biopsy, tumor, spleen, bone marrow, cord blood, CD34⁺ cells, monocytes, and adherent cells by exposing said precursor cells to one or more cytokines.

8. The method of claim 7 wherein the cytokines comprise GM-CSF.

9. The method of claim 7 wherein the cytokines comprise IL-4.

10. The method of claim 7 wherein the cytokines comprise GM-CSF and IL-4.

11. The method of claim 7 wherein the cytokines comprise IL-13.

12. The method of claim 7 wherein the cytokines comprise GM-CSF and IL-13.

13. The method of claim 7 wherein the source of precursor cells comprises leukapheresis product.

14. The method of claim 7 wherein the source of precursor cells comprises peripheral blood.

15. The method of claim 7 wherein the source of precursor cells comprises bone marrow.

16. The method of claim 7 wherein the source of precursor cells comprises cord blood.

17. The method of claim 7 wherein the source of precursor cells comprises CD34⁺ cells.

18. The method of claim 7 wherein the source of precursor cells comprises monocytes.

19. The method of claim 7 wherein the source of precursor cells comprises adherent cells.

20. The method of claim 1 wherein the immature dendritic cells are generated from a source of precursor cells selected from the group consisting of leukapheresis product, peripheral blood, lymph node, skin, GALT, tonsil, thymus, tissue biopsy, tumor, spleen, skin, bone marrow, cord blood, CD34⁺ cells, monocytes, and adherent cells by exposing said precursor cells to one or more cytokines and activated T cells or supernatant therefrom.

21. The method according to claim 1 wherein the immature dendritic cells are loaded with antigen through gene modification or by exposing the immature dendritic cells to a source of antigen selected from the group consisting of protein, peptides, tumor lysate, and apoptotic bodies.

22. The method according to claim 21 wherein the source of antigen comprises protein.

23. The method according to claim 21 wherein the source of antigen comprises peptides and/or polypeptides

24. The method according to claim 21 wherein the source of antigen comprises tumor lysates.

25. The method according to claim 21 wherein the source of antigen comprises apoptotic bodies.

26. The method according to claim 21 wherein the source of antigen comprises irradiated tumor cells from a tumor or a cell line.

27. The method according to claim 1 wherein the dendritic cells are genetically modified.

28. The method of claim 1 wherein the activated T cells comprise a T cell line.

29. The method of claim 1 wherein the activated T cells are generated by cell surface moiety ligation comprising:

(a) providing a population of cells wherein at least a portion thereof comprises T cells; and

(b) exposing the population of cells to an agent that induces activation of said T cells.

30. The method of claim 29 wherein the agent comprises anti-T cell receptor antibodies.

31. The method of claim 29 wherein the agent comprises anti-CD3 antibodies.

32. The method of claim 29 wherein the agent comprises anti-CD28 antibodies.

33. The method of claim 29 wherein the agent comprises anti-CD3 and anti-CD28 antibodies.

34. The method of claim 1 wherein the activated T cells are generated by simultaneous T cell concentration and cell surface moiety ligation, comprising:

(a) providing a population of cells wherein at least a portion thereof comprises T cells;

(b) exposing the population of cells to a surface, wherein the surface has attached thereto one or more agents that ligate a cell surface moiety of at least a portion of the T cells and stimulates at least a portion of T cells.

(c) applying a force that predominantly drives T cell concentration and T cell surface moiety ligation, thereby inducing T cell stimulation.

35. A population of mature dendritic cells generated according to the method of claim 1.

36. A population of mature dendritic cells according to claim 35 wherein the dendritic cells are fused to tumor cells to form dendritic/tumor cell fusions.

37. A composition comprising the dendritic/tumor cell fusions according to claim 36 and a pharmaceutically acceptable excipient.

38. A method for stimulating an immune response in a mammal comprising, administering to the mammal the composition of claim 37.

39. A method for reducing the presence of cancer cells in a mammal comprising, exposing the cells to the composition of claim 37.

40. A method for inhibiting the development of a cancer in a mammal, comprising administering to the mammal the composition of claim 37.

41. A composition comprising the dendritic cells according to claim 35 and a pharmaceutically acceptable excipient.

42. A composition according to claim 41 wherein the dendritic cells are genetically modified.

43. A method for stimulating an immune response in a mammal comprising, administering to the mammal the composition of claim 41.

44. The method of claim 43 wherein the immune response comprises the activation of T cells in the mammal.

45. A method for ameliorating an immune response dysfunction in a mammal comprising administering to the mammal the composition of claim 41.

46. A method for reducing the presence of cancer cells in a mammal comprising, exposing the cells to the composition of claim 41.

47. The method of claim 46 wherein the cancer cells are from a cancer selected from the group consisting of melanoma, non-Hodgkin'"'"'s lymphoma, Hodgkin'"'"'s disease, leukemia, acute lymphoblastic leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, and chronic lymphocytic leukemia.

48. The method of claim 46 wherein the cancer comprises leukemia.

49. A method for reducing the presence of an infectious organism in a mammal comprising, administering to the mammal the composition of claim 41.

50. A method for inhibiting the development of a cancer in a mammal, comprising administering to the mammal the composition of claim 41.

51. The method of claim 50 wherein the cancer is selected from the group consisting of melanoma, non-Hodgkin'"'"'s lymphoma, Hodgkin'"'"'s disease, leukemia, acute lymphoblastic leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, and chronic lymphocytic leukemia.

52. The method of claim 50 wherein the cancer comprises leukemia.

53. A method for inhibiting the development of an infectious disease in a mammal, comprising administering to the mammal the composition of claim 41.

54. A composition comprising dendritic cells and activated T cells wherein the dendritic cells have been matured by exposure to activated T cells or supernatant therefrom ex vivo.

55. The composition of claim 54, further comprising a pharmaceutically acceptable excipient.

56. A method for stimulating an immune response in a mammal, comprising administering to the mammal the composition of claim 55.

57. A method for inhibiting the development of a cancer in a mammal, comprising administering to the mammal the composition of claim 55.

58. The method of claim 57 wherein the cancer is selected from the group consisting of melanoma, non-Hodgkin'"'"'s lymphoma, Hodgkin'"'"'s disease, leukemia, plasmocytoma, sarcoma, glioma, thymoma, breast cancer, prostate cancer, colo-rectal cancer, kidney cancer, renal cell carcinoma, pancreatic cancer, esophageal cancer, brain cancer, lung cancer, ovarian cancer, cervical cancer, multiple myeloma, hepatomocellular carcinoma, acute lymphoblastic leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, and chronic lymphocytic leukemia.

59. The method of claim 57 wherein the cancer comprises leukemia.

60. A method for inhibiting the development of an infectious disease in a mammal, comprising administering to the mammal the composition of claim 55.

61. A method for reducing the presence of cancer cells in a mammal, comprising administering to the mammal a composition comprising, dendritic cells matured by activated T cells or supernatant therefrom ex vivo, activated T cells, and a pharmaceutically acceptable excipient.

62. The method of claim 61 wherein the cancer cells are selected from the group consisting of a melanoma, non-Hodgkin'"'"'s lymphoma, Hodgkin'"'"'s disease, leukemia, plasmocytoma, sarcoma, glioma, thymoma, breast cancer, prostate cancer, colo-rectal cancer, kidney cancer, renal cell carcinoma, pancreatic cancer, esophageal cancer, brain cancer, lung cancer, ovarian cancer, cervical cancer, multiple myeloma, hepatocellular carcinoma, acute lymphoblastic leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, and chronic lymphocytic leukemia.

63. The method of claim 61 wherein the cancer cells comprise leukemia.

64. A method for generating mature dendritic cells in vivo comprising, administering to a mammal a composition comprising activated T cells.

65. A method for generating mature dendritic cells, comprising:

(a) generating immature dendritic cells in vitro from a source of precursor cells by a method selected from the group consisting of;

i. exposing the precursor cells to GM-CSF and IL-4;

ii. exposing the precursor cells to GM-CSF and IL-13;

iii. exposing the precursor cells to activated T cells or supernatant therefrom;

iv. exposing the precursor cells to GM-CSF and IL-4 and activated T cells or supernatant therefrom; and

v. exposing the precursor cells to GM-CSF and IL-13 and activated T cells or supernatant therefrom;

(b) administering to a mammal the immature dendritic cells of part (a), and;

(c) administering to the mammal activated T cells, thereby inducing in vivo maturation of the immature dendritic cells.

66. The method of claim 65 wherein the source of precursor cells is selected from the group consisting of leukapheresis product, peripheral blood, lymph node, skin, GALT, tonsil, thymus, tissue biopsy, tumor, spleen, skin, bone marrow, cord blood, CD34⁺ selected cells, monocytes, and adherent cells.

67. The method of claim 65 wherein the source of precursor cells is leukapheresis product.

68. The method of claim 65 wherein the source of precursor cells is peripheral blood.

69. The method of claim 65 wherein the source of precursor cells is bone marrow.

70. The method of claim 65 wherein the source of precursor cells is cord blood.

71. The method of claim 65 wherein the source of precursor cells is CD34⁺ cells.

72. The method of claim 65 wherein the source of precursor cells is monocytes.

73. The method of claim 65 wherein the source of precursor cells is adherent cells.

75. The method of claim 65 wherein the precursor cells are isolated from peripheral blood.

76. The method of claim 65 wherein the precursor cells are isolated from leukapheresis product.

77. The method of claim 76 wherein the activated T cells are generated by a method comprising, exposing the population of T cells to an anti-CD3 antibody and a ligand which binds an accessory molecule on the surface of the T cells, under conditions appropriate for activation of the T cells.

78. The method of claim 76 wherein said activated T cells are generated by a method comprising:

(a) exposing the population of T cells to an anti-CD3 antibody which is immobilized on a solid phase surface; and

;

(b) stimulating an accessory molecule on the surface of the T cells with an anti-CD28 antibody, wherein said anti-CD28 antibody is immobilized on the same solid phase surface as the anti-CD3 antibody, thereby inducing activation and proliferation of the T cells.

79. The method of claim 78 wherein the activated T cells generated comprise T cells that have proliferated.

80. The method of claim 78 wherein the activated T cells generated comprise T cells that secrete cytokines.

74. A method for generating mature dendritic cells, comprising:

(a) obtaining a population of cells from a mammal wherein at least a portion thereof comprises precursor dendritic cells;

(b) exposing said portion of cells in vitro to GM-CSF and IL-4 or IL-13 to generate immature dendritic cells; and

(c) exposing said immature dendritic cells in vitro to a population of activated T cells or supernatant therefrom for a sufficient period of time to achieve desired maturation.

81. A method for expanding dendritic/tumor cell fusions comprising exposing the dendritic/tumor cell fusions to activated T cells or supernatant therefrom.